Ampullary Cancer clinical trials at UCSF
1 research study open to eligible people
Showing trials for
CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
open to eligible people ages 18 years and up
This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.
San Francisco, California and other locations
Our lead scientists for Ampullary Cancer research studies include Katie Kelley, MD.
Last updated: